Krahasoni metodat
Shqyrtoni metodat e zgjedhura krah për krah; rreshtat që ndryshojnë janë të theksuar.
| Faza II e Provës Klinike Bayesiane× | Provë Klinike Ad-hoc e Fazi II× | |
|---|---|---|
| Fusha | Epidemiologji | Epidemiologji |
| Familja | Process / pipeline | Process / pipeline |
| Viti i origjinës≠ | 1990s (Thall & Simon 1994; Berry 1985–2006) | 1994 (formal framework); widespread adoption 2000s–2010s |
| Krijuesi≠ | Peter Thall, Richard Simon, Donald Berry (key contributors) | Peter Bauer & Klaus Kohne (formal statistical framework, 1994); broader adaptive trial methodology developed through FDA and ICH guidance in the 2000s |
| Lloji≠ | Interventional clinical trial design | Experimental clinical trial design |
| Burimi themelues≠ | Thall, P. F., & Simon, R. (1994). Practical Bayesian guidelines for phase IIB clinical trials. Biometrics, 50(2), 337–349. DOI ↗ | Bauer, P., & Kohne, K. (1994). Evaluation of experiments with adaptive interim analyses. Biometrics, 50(4), 1029–1041. DOI ↗ |
| Emërtime të tjera | Bayesian phase 2 trial, Bayesian single-arm phase II study, Bayesian early-phase efficacy trial, Bayes phase II | Adaptive Ph II trial, seamless adaptive Phase II, adaptive dose-finding trial, response-adaptive Phase II |
| Të lidhura≠ | 6 | 1 |
| Përmbledhja≠ | A Bayesian Phase II clinical trial applies Bayesian statistical inference to the standard Phase II objective of evaluating whether an experimental treatment shows sufficient early-phase efficacy to justify progression to a Phase III trial. By combining prior information with accumulating trial data, it enables principled interim monitoring, flexible stopping rules, and updated probability statements about treatment effect — all without the multiple-testing penalties that burden frequentist sequential designs. | An adaptive Phase II clinical trial is a prospective experimental design in which pre-specified rules allow the study protocol to be modified — such as dropping arms, adjusting sample size, or narrowing the patient population — based on accumulating interim data, without inflating the Type I error rate. The design is widely used in early-phase drug development to screen candidate doses or treatments efficiently while preserving statistical validity. |
| ScholarGateSeti i të dhënave ↗ |
|
|